Journal de gestion et de thérapie de la douleur


A brief note on kaposi sarcoma in HIV/AIDS patients.

Issac Ivan*

Kaposi Sarcoma (KS) is a rare form of cancer primarily affecting the skin, but it can also involve other organs. Its association with HIV/AIDS has been well-established, and it is considered an AIDS-defining illness. This brief note provides an overview of KS in HIV/AIDS patients, including its epidemiology, clinical features, and treatment options. The incidence of KS increased with the HIV/AIDS pandemic, particularly in individuals with low CD4 cell counts. KS can present in various forms, including classic, endemic, epidemic, and iatrogenic. Treatment options depend on factors such as disease extent, immune status, and symptoms. Highly active antiretroviral therapy (HAART) is a key component of KS management, while localized therapies, systemic therapies (chemotherapy and immunotherapy), and anti-HHV-8 therapy may be employed based on individual patient characteristics. Supportive care measures are essential in improving quality of life. Ongoing research and advancements in treatment modalities offer hope for improved outcomes in KS patients with HIV/AIDS.